Immunome, Inc.

6 articles with Immunome, Inc.

• Immunome Reports Third Quarter 2020 Financial Results and Significant Progress

  11/17/2020

  Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced third quarter 2020 financial results and recent highlights.

• Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering

  10/13/2020

  Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases, including COVID-19, today announced the full exercise of the underwriters' option to purchase an additional 487,500 shares of common stock at the public offering price of $12.00 per share, resulting in add

• Immunome Announces Pricing of Upsized Initial Public Offering

  10/2/2020

  Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated, today announced the pricing of its initial public offering.

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Immunome Announces Creation of COVID-19 Advisory Board

  9/16/2020

  Advisory Board to help guide development and clinical testing of biosynthetic convalescent plasma as a potential COVID-19 treatment and prevention of disease

• Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19

  7/28/2020

  Up to $13.3M funding to accelerate development and early clinical testing of antibodies derived from large-scale B cell interrogation of COVID-19 “Super-Responders”